



**PHILIPS**

Computed tomography

Lung cancer screening

Successful  
**lung  
cancer  
screening**  
starts here



# Lung cancer is the most common cause of cancer death

Lung cancer has higher worldwide mortality than colorectal, breast, and prostate cancers combined.\*

13%

of all new cancer cases diagnosed are lung\*\*

## The earlier, the better

Low-dose CT lung cancer screening has been shown to detect lung cancer at earlier stages when it is more curable.<sup>1,2</sup>

20%

mortality reduction

with CT lung cancer screening<sup>1</sup>

## Screening requires more than a scan

**A successful lung cancer screening program requires a comprehensive solution from the start, with support to address the challenges a screening program presents.**



### Effectiveness

with growing the program



### Compliance

with CMS-approved registry reporting



### Organization

to streamline program management

\*American Cancer Society key statistics for lung cancer, 2016.  
\*\*World Cancer Research Fund International Fact Sheet, 2015.

# Strong support, at every step



## 1

### Program set-up

Our specialist teams provide consultative services to help you get up and running.

- Best practices
- Outreach to attract referrals

## 2

### Education

We help guide you to continuously learn from thought-leaders.

- Web-based education
- Quality and consistency



## 3

### Scanning

We offer a full portfolio of systems, each complying with ACR guidelines:

- Protocols with  $CTDI_{vol}$  of  $\leq 3 \text{ mGy}^{13}$
- Acquisitions  $\leq 15 \text{ sec}$
- All systems use active DoseRight dose modulation to automatically adjust dose



## 4

### Advanced visualization with **IntelliSpace Portal (ISP)**

With Lung-RADS classification automatically calculated, ISP offers streamlined workflow to help you detect, diagnose, and follow up on lung nodules.



## 5

### Patient management

We provide a program that's built for screening so that you operate compliantly and efficiently.

- Automated routine administrative and instructive tasks
- Patient follow-up and tracking
- Uploading to CMS-approved registry



## We'll help you put it all together

Superb images for confident diagnosis.

The low dose required for lung cancer screening.

And a well-integrated program from the start.

### iDose<sup>4</sup>


Personalized image quality based on patients' needs at low dose

### IMR

Industry-leading low-contrast resolution and virtually noise-free images<sup>††</sup>

### iPatient

Patient-centric imaging that puts you in control of important advances in dose management and workflow



<sup>†</sup> CT dose index ( $CTDI_{vol}$ ) of  $\leq 3.0 \text{ mGy}$  (milligray) for standard size patients (defined to be 5' 7" and approximately 155 pounds) with appropriate reductions in  $CTDI_{vol}$  for smaller patients and appropriate increases in  $CTDI_{vol}$  for larger patients.

<sup>††</sup> In clinical practice, the use of IMR may reduce CT patient dose depending on the clinical task, patient size, anatomical location, and clinical practice. A consultation with a radiologist and a physicist should be made to determine the appropriate dose to obtain diagnostic image quality for the particular clinical task. Low-contrast detectability and noise were assessed using Reference Body Protocol comparing IMR to FBP; measured on 0.8 mm slices, tested on the MITA CT IQ Phantom (CCT183, The Phantom Laboratory), using human observers.

# The systems for your set-up

From advanced oncology to dedicated chest exams, Philips offers CT and PET/CT systems to meet a range of clinical and economic needs in lung cancer screening.

<b>Spectral CT</b> On-demand color quantification	<b>iCT</b> State-of-the- art acquisitions	<b>Ingenuity</b> A family of confidence	<b>Brilliance</b> Everyday brilliance	<b>Big Bore CT</b> Open to the opportunity	<b>Digital PET/CT</b> World's first digital PET/CT	<b>GEMINI/ TruFlight</b> High- performance PET/CT
IQon Spectral CT	Brilliance iCT SP	Ingenuity Core	Brilliance CT 40	Brilliance CT Big Bore	Vereos PET/CT (64 and 128)	GEMINI TF PET/CT (64)
	Brilliance iCT	Ingenuity Core <sup>128</sup>	Brilliance CT 64	Brilliance CT Big Bore Radiology		GEMINI 16 Power PET/CT (16)
	iCT TVI	Ingenuity CT	Brilliance CT 64 with Essence technology	Brilliance CT Big Bore Oncology		GEMINI TF PET/CT (16)
	iCT Elite	Ingenuity Elite	Brilliance 16	GEMINI TF Big Bore PET/CT		TruFlight Select PET/CT (16)
		Ingenuity TF PET/CT (64 and 128)	Brilliance 16 Power			GEMINI TF Ready PET/CT (16)
		Ingenuity Flex				GEMINI LXL PET/CT (16)

## Let's get started

We have the systems and solutions to help make your lung cancer screening program productive from the beginning. To learn more, visit [www.philips.com/CT](http://www.philips.com/CT).

1. The National Lung Screening Trial research team. Reduced lung cancer mortality with low dose computed tomographic screening. N Engl J Med, 2011;365:395-409.
2. Henschke CI, Yankelevitz DF, Libby DM, Pasmantier MW, Smith JP, and Miettinen OS. Survival of patients with Stage I lung cancer detected on CT screening. N Engl J Med 2006;355:1763-71.
3. Decision Memo for Screening for Lung Cancer with Low Dose Computed Tomography (LDCT) (CAG-00439N), <https://www.cms.gov/medicare-coverage-database/details/nca-decision-memo.aspx?NCAId=274>.

iDose<sup>4</sup> and IMR not available on Brilliance 16. IMR not available on Big Bore CT.  
The screening must be performed within the established inclusion criteria of programs/ protocols that have been approved and published by either a governmental body or professional medical society. Please refer to clinical literature, including the results of the National Lung Screening Trial (N Engl J Med 2011;365:395-409) and subsequent literature, for further information.

© 2016 Koninklijke Philips N.V. All rights are reserved. Philips reserves the right to make changes in specifications and/or to discontinue any product at any time without notice or obligation and will not be liable for any consequences resulting from the use of this publication. Trademarks are the property of Koninklijke Philips N.V. or their respective owners.



[www.philips.com](http://www.philips.com)

Printed in The Netherlands.  
4522 991 18881 \* APR 2016